Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
Zhengfei ZhuTiantian GuoFei LiangZezhou WangJunhua ZhangJianjiao NiZhengfei ZhuPublished in: Cancer (2024)
In patients with metastatic EGFR/ALK wild-type NSCLC without baseline BMs, adding atezolizumab in the first-line treatment might not reduce the CI-BM. However, the administration of bevacizumab may reduce the risk of BMs.
Keyphrases
- small cell lung cancer
- brain metastases
- wild type
- case report
- advanced non small cell lung cancer
- electronic health record
- white matter
- resting state
- big data
- squamous cell carcinoma
- epidermal growth factor receptor
- functional connectivity
- cerebral ischemia
- machine learning
- multiple sclerosis
- brain injury
- blood brain barrier
- subarachnoid hemorrhage
- data analysis
- artificial intelligence